A method for treating conditions associated with HIV infection, selected from Acquired Immune Deficiency Syndrome (AIDS), progressive generalized lymphadenopathy (PGL), HIV-mediated dementia and multiple sclerosis, comprising administering a therapeutically-effective amount of a compound to a patient having HIV infection, said compound having the formula
- a N-oxide, stereoisomeric form or salt thereof,
- wherein
- a is zero, 1, 2, 3, 4 or 5;
- L is C1-4alkanediyl;
- R1 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12cycloalkyl, Het, aryl or C1-10alkyl substituted with a substituent selected from the group consisting of Het, aryl, C3-12cycloalkyl, amino and mono- or disubstituted amino wherein the substituents on the amino group are each individually selected from C1-10alkyl, C2-10alkenyl, C3-12cycloalkyl, Het and aryl;
- R2 is hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12cycloalkyl, Het, aryl or C1-10alkyl substituted with a substituent selected from the group consisting of Het, aryl, C3-12cycloalkyl, amino and mono- or disubstituted amino wherein the substituents on the amino group are each individually selected from C1-10alkyl, C2-10alkenyl, C3-12cycloalkyl, Het and aryl;
- or
- R1 and R2 taken together with the nitrogen atom to which they are attached form a 5 to 12 membered saturated or partially saturated heterocycle with one or more heteroatoms each individually selected from nitrogen, oxygen or sulfur, and wherein said heterocycle may optionally be substituted with C1-10alkyl,
- C2-10alkenyl, C2-10alkynyl, C3-12cycloalkyl, C1-6alkyloxycarbonyl, Het, aryl or
- C1-10alkyl substituted with a substituent selected from the group consisting of Het, aryl, C3-12cycloalkyl, amino and mono- or disubstituted amino wherein the substituents on the amino group are each individually selected from C1-10alkyl,
- C2-10alkenyl, C3-12cycloalkyl, Het and aryl;
- R3 is carboxyl, halogen, nitro, C1-10alkyl, C3-12cycloalkyl, polyhaloC1-10alkyl, cyano, amino, mono- or disubstituted amino, aminocarbonyl, mono- or disubstituted aminocarbonyl, C1-10alkyloxy, C1-10alkylthio, C1-10alkylsulfonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl or piperazinyl optionally substituted with C1-10alkyl, wherein the substituents on any of the amino groups are each individually selected from C1-10alkyl, C2-10alkenyl, C3-12cycloalkyl, Het and aryl;
- aryl is phenyl optionally substituted with one or more substituents selected from the group consisting of C1-10alkyl, polyhaloC1-10alkyl, C1-10alkyloxy, C1-10alkylthio, C1-10alkylsulfonyl, nitro, cyano, halo, C3-7cycloalkyl, C1-10alkylcarbonyl, carboxyl, C1-10alkyloxycarbonyl, amino, mono- or disubstituted amino, aminocarbonyl, mono- or disubstituted aminocarbonyl, wherein the substituents on any of the amino groups are each individually selected from phenyl, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, pyrrolidinyl, piperidinyl, homopiperidinyl or piperazinyl optionally substituted with C1-10alkyl;
- Het is a 5 or 6 membered aromatic, saturated or partially saturated, monocyclic heterocycle with one or more heteroatoms each individually selected from nitrogen, oxygen or sulfur, and which heterocycle may optionally be substituted by one, or where possible, more than one substituent selected from the group consisting of C1-10alkyl, polyhaloC1-10alkyl, C1-10alkyloxy, C1-10alkylthio,
- C1-10alkylsulfonyl, nitro, cyano, halo, C3-7cycloalkyl, C1-10alkylcarbonyl, carboxyl, C1-10alkyloxycarbonyl, amino, mono- or disubstituted amino, aminocarbonyl, mono- or disubstituted aminocarbonyl, wherein the substituents on any of the amino groups are each individually selected from phenyl, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, pyrrolidinyl, piperidinyl, homopiperidinyl or piperazinyl optionally substituted with C1-10alkyl.